Smithkline Beecham Corporation

Glaxo Group Limited

Smithkline Beechman Corporation

Deirdre Mary Bernadette Hickey

Stephen Allan Smith

Colin Andrew Leach

Ivan Leo Pinto

Robert John Ife

John Liddle

Alan D Borthwick

Andrew McMurtrie Mason

Steven James Stanway

Colin Houston MacPhee

David Graham Tew

Paul Graham Wyatt

Anna Katrin Szardenings

Christopher Donald Southan

Israel Simon Gloger

Neil Derek Miller

Steven Leslie Sollis

David George Hubert Livermore

Simon Quentyn John Rice

Richard Jonathan Hatley

Geoffrey Mark Prouse Lawrence

Fabrizio Nerozzi

Roderick Alan Porter

Richard Leonard Elliott

Ashley Edward Fenwick

Compounds of formula (I) wherein Ris 2-indanyl, Ris 1-methylpropyl, Ris a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, Rrepresents methyl and Rrepresents hydrogen or methyl or, Rand Rtogether with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

Compounds

Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in treating atherosclerosis.

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.

Substituted diketopiperazines as oxytocin antagonists

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Compounds of formula (I) wherein Ris 2-indanyl, Ris 1-methylpropyl, Ris a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, Rrepresents methyl and Rrepresents hydrogen or methyl or, Rand Rtogether with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

5,6-trimethylenepyrimidin-4-one compounds

Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in treating atheroscelerosis.

Pyrimidine compounds

Piperazinediones as oxytocin receptor antagonists

A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a mammal in need thereof of an effective amount of a compound of the formula (I) and/or a physiologically acceptable derivative thereof, wherein the substituents have the meaning given in the description. Disclosed are also novel compounds of formula (I) and processes for their preparation.

Compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in therapy, in particular for treating atherosclerosis.

Pyrimidinone derivatives and their use in the treatment of atherosclerosis

The enzyme Lp-PLAin purified form, an isolated nucleic acid molecule encoding Lp-PLA, the use of an inhibitor of the enzyme Lp-PLAin therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.

Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy

Pyridinone derivatives for treatment of atherosclerosis

Growing community of inventors

Stevenage, United Kingdom

Deirdre Mary Bernadette Hickey